5EKI | pdb_00005eki

Crystal Structure of Truncated CCL21

  • Classification: IMMUNE SYSTEM
  • Organism(s): Homo sapiens
  • Expression System: Escherichia coli
  • Mutation(s): No 

  • Deposited: 2015-11-03 Released: 2016-10-05 
  • Deposition Author(s): Lewandowski, E.M., Smith, E.W., Chen, Y.
  • Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS), National Institutes of Health/National Cancer Institute (NIH/NCI)

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free: 
    0.262 (Depositor), 0.263 (DCC) 
  • R-Value Work: 
    0.210 (Depositor), 0.217 (DCC) 
  • R-Value Observed: 
    0.213 (Depositor) 

wwPDB Validation 3D Report Full Report

Validation slider image for 5EKI

This is version 1.4 of the entry. See complete history

Literature

Crystallographic Structure of Truncated CCL21 and the Putative Sulfotyrosine-Binding Site.

Smith, E.W.Lewandowski, E.M.Moussouras, N.A.Kroeck, K.G.Volkman, B.F.Veldkamp, C.T.Chen, Y.

(2016) Biochemistry 55: 5746-5753

  • DOI: https://doi.org/10.1021/acs.biochem.6b00304
  • Primary Citation Related Structures: 
    5EKI

  • PubMed Abstract: 

    CCL21 chemokine binds the G protein-coupled receptor CCR7, aiding not only in immune response but also in cancer metastasis. Compared with other chemokines, CCL21 has a unique extended unstructured C-terminus that is truncated in some naturally occurring variants. We have determined the X-ray crystallographic structure of a truncated CCL21 (residues 1-79) lacking the extended C-terminus and identified, via two-dimensional nuclear magnetic resonance (NMR), a putative sulfotyrosine-binding site that may recognize such post-translationally modified tyrosine residues on the receptor. Compared to the previously determined NMR structure of full-length CCL21, the crystal structure presents new druggable binding hot spots resulting from an alternative N-loop conformation. In addition, whereas the previous NMR structure did not provide any structural information after residue 70, the C-terminus of the truncated CCL21, ordered up to Ala77 in our crystal structure, is placed near the N-loop and sulfotyrosine-binding site, indicating that the extended C-terminus of full-length CCL21 can interact with this important region for receptor binding. These observations suggest a potential origin for the autoinhibition of CCL21 activity that was recently described. The new crystal structure and binding hot spot analysis have important implications for the function of the CCL21 C-terminus and drug discovery.


  • Organizational Affiliation
    • Department of Molecular Medicine, University of South Florida , Tampa, Florida 33612, United States.

Macromolecule Content 

  • Total Structure Weight: 53.67 kDa 
  • Atom Count: 3,639 
  • Modeled Residue Count: 427 
  • Deposited Residue Count: 474 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
C-C motif chemokine 21
A, B, C, D, E
A, B, C, D, E, F
79Homo sapiensMutation(s): 0 
Gene Names: CCL21SCYA21UNQ784/PRO1600
UniProt & NIH Common Fund Data Resources
Find proteins for O00585 (Homo sapiens)
Explore O00585 
Go to UniProtKB:  O00585
PHAROS:  O00585
GTEx:  ENSG00000137077 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupO00585
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.90 Å
  • R-Value Free:  0.262 (Depositor), 0.263 (DCC) 
  • R-Value Work:  0.210 (Depositor), 0.217 (DCC) 
  • R-Value Observed: 0.213 (Depositor) 
Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 65.752α = 90
b = 58.244β = 119.94
c = 66.054γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
HKL-2000data scaling
SCALEPACKdata scaling
DENZOdata reduction
BALBESphasing
MOLREPphasing

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesR01 GM097381
National Institutes of Health/National Cancer Institute (NIH/NCI)United States1R15CA159202-01

Revision History  (Full details and data files)

  • Version 1.0: 2016-10-05
    Type: Initial release
  • Version 1.1: 2016-10-19
    Changes: Database references
  • Version 1.2: 2017-09-20
    Changes: Author supporting evidence, Database references, Derived calculations, Refinement description
  • Version 1.3: 2019-12-04
    Changes: Author supporting evidence
  • Version 1.4: 2024-10-16
    Changes: Data collection, Database references, Structure summary